Evidence map›Paper›PMID 40740925›Full record

ReviewWorld journal of gastrointestinal surgery2025

Predicting neoadjuvant chemoradiotherapy response in rectal cancer: Insights from biomarkers to clinical practice.

Hikmet Pehlevan-Özel, Eda Şahingöz, Mert Altaş, Mesut Tez

Abstract readReview
In one paragraph

Review in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hikmet Pehlevan-ÖzelDepartment of Surgery, Ankara City Hospital, Ankara 06800, Türkiye.
Eda ŞahingözDepartment of General Surgery, University of Health Sciences, Ankara 06100, Türkiye.
Mert AltaşDepartment of Surgery, Ankara Bilkent City Hospital, Ankara 06800, Türkiye.
Mesut TezDepartment of Surgery, University of Health Sciences, Ankara City Hospital, Ankara 06800, Türkiye. mesuttez@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rectal cancer poses a major global health challenge, with neoadjuvant chemoradiotherapy improving outcomes in locally advanced cases by reducing tumor burden and recurrence risk. However, response variability, including only 15%-20% of patients achieving pathological complete response, underscores the urgent need for accurate predictive tools. This review explored current and emerging biomarkers to enhance neoadjuvant chemoradiotherapy response prediction and inform clinical practice.

Indexed as

BiomarkersClinical predictorsNeoadjuvant chemoradiotherapyPathological complete responseRadiomicsRectal cancerTumor regression grading

Identifiers

PMID40740925
PMCPMC12305255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.